Support comes from studies investigating the effects of FXR activation by 6-ethyl-chenodeoxycholic acid, a potent activator of FXR, in rats with diabetes mellitus, obesity, insulin resistance, and liver steatosis [106]. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.